Final FDA nod for Zydus generic Revlimid

Indian drugmaker Zydus Lifesciences (NSE: ZYDUSLIFE) has been granted approval by the US Food and Drug Administration (FDA) to market lenalidomide capsules.

The company, formerly known as Cadila Healthcare, has received final approvals for 5mg, 10mg, 15mg and 25mg strengths and tentative approvals for 2.5mg and 20mg strength capsules.

Just last week, another Indian drugmaker, Dr Reddy’s Laboratories (BSE: 500124), launched its generic version of Bristol Myers Squibb’s (NYSE: BMY) cancer drug Revlimid (lenalidomide), saying it  was eligible for 180 days of first-to-market generic drug exclusivity.